(People's Daily health client Wang Yuan)
On the afternoon of April 3, Sinopharm China Biologics announced that its second-generation recombinant protein COVID-19 vaccine had received clinical trial approval documents issued by the State Drug Administration.
The vaccine is developed by Sinopharm Zhongsheng Biotechnology Research Institute / National Engineering Research Center for New Vaccines, and has independent intellectual property rights. According to the relevant clinical trial data, the second-generation recombinant protein new crown vaccine has shown good results on variants such as Omiclon.
R&D personnel of the Chinese Academy of Biological Research in the laboratory. Picture according to Chinese biology.
The second-generation recombinant COVID-19 vaccine (NVSI-06-08) is a computational structure vaccine technology platform independently established by the Chinese Academy of Biology, based on the first-generation recombinant COVID-19 vaccine (NVSI-06-07), which is designed and developed by computationally analyzing the evolutionary laws and immune escape ability of the mutation sites of epidemic strains.
On December 27, 2021, the UAE Ministry of Health and Prevention approved the emergency use license for Sinopharm's China Bio-Ii Recombinant Protein COVID-19 vaccine, becoming the world's first second-generation COVID-19 vaccine approved for emergency use. According to China Biologics, the current research results show that the vaccine has good safety and tolerability, which can stimulate the human body to produce high-level neutralizing antibodies against prototype strains and major variant strains, reflecting the advantages and characteristics of the recombinant protein vaccine technology route in vaccine research and development.
2022.2.16China Institute of Biology: "Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2". Cell Discovery
